ExPLoRNA Therapeutics
PrivateLast Round
Grant
Dec 7, 2022
Total Funding Raised
$7.02M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
ExPLoRNA Therapeutics is a biotechnology company that develops messenger ribonucleic acid (mRNA) therapeutics and provides proprietary cap analog technology to pharmaceutical partners for use in vaccines and therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ExPLoRNA Therapeutics Comparables
Compare ExPLoRNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Maravai Lifesciences Holdings, Inc. | 79% | |
| BOC Sciences | 79% | |
| Hongene Biotechnology | 77% |
ExPLoRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 7, 2022 | ||||
| VC Round | Mar 30, 2021 | ||||
| Grant | Dec 20, 2019 |
ExPLoRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Regional Development Fund | Grant |
| Gates Foundation | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
| European Union | Grant |
| Agencja Badań Medycznych | Grant |
| National Centre for Research and Development | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 254% MoM, reaching 3.1K.
- Mar 3, 2026
Monthly visitors grew 79% MoM, reaching 351.
Recent news
Latest coverage and updates
- partners_withSep 29, 2026
ExploRNA Therapeutics partners with Wacker Group.
- partners_withSep 22, 2026
ExploRNA Therapeutics partnered with Lukasiewicz on Sep 22nd '26.
- attends_eventJul 23, 2026
ExploRNA Therapeutics attended event EUROBIOTECH 2026 on Jul 1st '26.
- attends_eventJul 23, 2026
ExploRNA Therapeutics attended event 10th Central European Congress of Life Sciences on Jul 1st '26.
ExPLoRNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ExPLoRNA Therapeutics's valuation, stock price, and market status.
Is ExPLoRNA Therapeutics a public or private company?
ExPLoRNA Therapeutics is a private company.
What is the current stock price of ExPLoRNA Therapeutics?
ExPLoRNA Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is ExPLoRNA Therapeutics worth (valuation)?
Valuation information for ExPLoRNA Therapeutics is not publicly available.
Can I buy ExPLoRNA Therapeutics stock?
ExPLoRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ExPLoRNA Therapeutics's last funding round?
ExPLoRNA Therapeutics's most recent funding round was Grant on December 7, 2022.
Who are the main investors in ExPLoRNA Therapeutics?
Key investors in ExPLoRNA Therapeutics include The Bill & Melinda Gates Foundation Trust.
Will ExPLoRNA Therapeutics IPO soon?
No public IPO plans have been announced for ExPLoRNA Therapeutics.
How can I track ExPLoRNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ExPLoRNA Therapeutics's secondary market activity and sign up for updates.